Combining a dipeptidyl peptidase‐4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and β‐cell function in <i>db/db</i> mice

Abstract

These results indicate that combination treatment with alogliptin and pioglitazone at an early stage of diabetes improved metabolic profiles and indices that measure beta-cell function, and maintained islet structure in db/db mice, compared with either alogliptin or pioglitazone monotherapy.